Cancer Research AACR Legacy  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mallikarjuna, G.
Right arrow Articles by Agarwal, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mallikarjuna, G.
Right arrow Articles by Agarwal, R.
[Cancer Research 64, 6349-6356, September 1, 2004]
© 2004 American Association for Cancer Research


Epidemiology and Prevention

Silibinin Protects against Photocarcinogenesis via Modulation of Cell Cycle Regulators, Mitogen-Activated Protein Kinases, and Akt Signaling

Gu Mallikarjuna1, Sivanandhan Dhanalakshmi1, Rana P. Singh1, Chapla Agarwal1,2 and Rajesh Agarwal1,2

1 Department of Pharmaceutical Sciences, School of Pharmacy, and 2 University of Colorado Cancer Center, University of Colorado Health Sciences Center, Denver, Colorado

Here, we assessed the protective effect of silibinin on UVB-induced skin carcinogenesis in SKH-1 hairless mice. Topical application of silibinin before or immediately after UVB exposure or its dietary feeding resulted in a strong protection against photocarcinogenesis, in terms of tumor multiplicity (60–66%; P < 0.001), tumor volume per mouse (93–97%; P < 0.001) and tumor volume per tumor (80–91%; P < 0.001). Silibinin also moderately inhibited tumor incidence (5–15%; P < 0.01) and delayed tumor latency period (up to 4 weeks; P < 0.01–0.001). To investigate in vivo molecular mechanisms of silibinin efficacy, tumors and uninvolved skin from tumor-bearing mice were examined immunohistochemically for proliferation, p53, apoptosis, and activated caspase-3. Silibinin treatment showed a strong decrease (P < 0.001) in proliferating cell nuclear antigen-positive cells and an increase in p53-positive (P < 0.005–0.001), terminal deoxynucleotidyltransferase-mediated nick end labeling-positive (P < 0.005–0.001), and cleaved caspase-3–positive cells (P < 0.001). Western blot analysis of normal skin and tumor lysates showed that silibinin decreases the levels of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 and associated cyclins A, E, and D1, together with an up-regulation of Cip1/p21, Kip1/p27, and p53. Silibinin also showed a strong phosphorylation of extracellular signal-regulated protein kinase 1/2, stress-activated protein kinase/c-JUN NH2-terminal kinase 1/2, and p38 mitogen-activated protein kinases but inhibited Akt phosphorylation and decreased survivin levels with an increase in cleaved caspase-3. Together, these results show a strong preventive efficacy of silibinin against photocarcinogenesis, which involves the inhibition of DNA synthesis, cell proliferation, and cell cycle progression and an induction of apoptosis. Furthermore, these results also identify in vivo molecular mechanisms of silibinin efficacy against photocarcinogenesis.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
C.-J. Lin, R. Sukarieh, and J. Pelletier
Silibinin inhibits translation initiation: implications for anticancer therapy
Mol. Cancer Ther., June 1, 2009; 8(6): 1606 - 1612.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. P. Singh, K. Raina, G. Deep, D. Chan, and R. Agarwal
Silibinin Suppresses Growth of Human Prostate Carcinoma PC-3 Orthotopic Xenograft via Activation of Extracellular Signal-Regulated Kinase 1/2 and Inhibition of Signal Transducers and Activators of Transcription Signaling
Clin. Cancer Res., January 15, 2009; 15(2): 613 - 621.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. K. Jung, K. W. Lee, S. Byun, N. J. Kang, S. H. Lim, Y.-S. Heo, A. M. Bode, G. T. Bowden, H. J. Lee, and Z. Dong
Myricetin Suppresses UVB-Induced Skin Cancer by Targeting Fyn
Cancer Res., July 15, 2008; 68(14): 6021 - 6029.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
R. P. Singh, G. Deep, M.-J. Blouin, M. N. Pollak, and R. Agarwal
Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft
Carcinogenesis, December 1, 2007; 28(12): 2567 - 2574.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Roy, M. Kaur, C. Agarwal, M. Tecklenburg, R. A. Sclafani, and R. Agarwal
p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells
Mol. Cancer Ther., October 1, 2007; 6(10): 2696 - 2707.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. A. Crowell, V. E. Steele, and J. R. Fay
Targeting the AKT protein kinase for cancer chemoprevention
Mol. Cancer Ther., August 1, 2007; 6(8): 2139 - 2148.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
M. C. Comelli, U. Mengs, C. Schneider, and M. Prosdocimi
Toward the Definition of the Mechanism of Action of Silymarin: Activities Related to Cellular Protection From Toxic Damage Induced by Chemotherapy
Integr Cancer Ther, June 1, 2007; 6(2): 120 - 129.
[Abstract] [PDF]


Home page
Integr Cancer TherHome page
G. Deep and R. Agarwal
Chemopreventive Efficacy of Silymarin in Skin and Prostate Cancer
Integr Cancer Ther, June 1, 2007; 6(2): 130 - 145.
[Abstract] [PDF]


Home page
Cancer Res.Home page
M. Gu, R. P. Singh, S. Dhanalakshmi, C. Agarwal, and R. Agarwal
Silibinin Inhibits Inflammatory and Angiogenic Attributes in Photocarcinogenesis in SKH-1 Hairless Mice
Cancer Res., April 1, 2007; 67(7): 3483 - 3491.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
R. P Singh and R. Agarwal
Mechanisms of action of novel agents for prostate cancer chemoprevention.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
C. Dwivedi, H. B. Valluri, X. Guan, and R. Agarwal
Chemopreventive effects of {alpha}-santalol on ultraviolet B radiation-induced skin tumor development in SKH-1 hairless mice
Carcinogenesis, September 1, 2006; 27(9): 1917 - 1922.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. Gu, R. P. Singh, S. Dhanalakshmi, S. Mohan, and R. Agarwal
Differential effect of silibinin on E2F transcription factors and associated biological events in chronically UVB-exposed skin versus tumors in SKH-1 hairless mice.
Mol. Cancer Ther., August 1, 2006; 5(8): 2121 - 2129.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. M. Meeran, S. Katiyar, C. A. Elmets, and S. K. Katiyar
Silymarin inhibits UV radiation-induced immunosuppression through augmentation of interleukin-12 in mice.
Mol. Cancer Ther., July 1, 2006; 5(7): 1660 - 1668.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
R. P. Singh, G. Deep, M. Chittezhath, M. Kaur, L. D. Dwyer-Nield, A. M. Malkinson, and R. Agarwal
Effect of silibinin on the growth and progression of primary lung tumors in mice.
J Natl Cancer Inst, June 21, 2006; 98(12): 846 - 855.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. P. Singh, S. Dhanalakshmi, S. Mohan, C. Agarwal, and R. Agarwal
Silibinin inhibits UVB- and epidermal growth factor-induced mitogenic and cell survival signaling involving activator protein-1 and nuclear factor-{kappa}B in mouse epidermal JB6 cells
Mol. Cancer Ther., May 1, 2006; 5(5): 1145 - 1153.
[Abstract] [Full Text] [PDF]


Home page
JDRHome page
P.-N. Chen, Y.-S. Hsieh, C.-L. Chiang, H.-L. Chiou, S.-F. Yang, and S.-C. Chu
Silibinin Inhibits Invasion of Oral Cancer Cells by Suppressing the MAPK Pathway
Journal of Dental Research, March 1, 2006; 85(3): 220 - 225.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Varghese, C. Agarwal, A. Tyagi, R. P. Singh, and R. Agarwal
Silibinin Efficacy against Human Hepatocellular Carcinoma
Clin. Cancer Res., December 1, 2005; 11(23): 8441 - 8448.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Ruiz, M. Santos, M. F. Lara, C. Segrelles, C. Ballestin, and J. M. Paramio
Unexpected Roles for pRb in Mouse Skin Carcinogenesis
Cancer Res., November 1, 2005; 65(21): 9678 - 9686.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Gu, S. Dhanalakshmi, S. Mohan, R. P. Singh, and R. Agarwal
Silibinin inhibits ultraviolet B radiation-induced mitogenic and survival signaling, and associated biological responses in SKH-1 mouse skin
Carcinogenesis, August 1, 2005; 26(8): 1404 - 1413.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Dhanalakshmi, C. Agarwal, R. P. Singh, and R. Agarwal
Silibinin Up-regulates DNA-Protein Kinase-dependent p53 Activation to Enhance UVB-induced Apoptosis in Mouse Epithelial JB6 Cells
J. Biol. Chem., May 27, 2005; 280(21): 20375 - 20383.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. Gu, S. Dhanalakshmi, R. P. Singh, and R. Agarwal
Dietary Feeding of Silibinin Prevents Early Biomarkers of UVB Radiation-Induced Carcinogenesis in SKH-1 Hairless Mouse Epidermis
Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1344 - 1349.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.